Vitruvian Partners LLP Acquires New Position in MaxCyte, Inc. $MXCT

Vitruvian Partners LLP acquired a new stake in MaxCyte, Inc. (NASDAQ:MXCT) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 5,043,356 shares of the company’s stock, valued at approximately $6,203,328,000. MaxCyte makes up about 3.1% of Vitruvian Partners LLP’s holdings, making the stock its 6th largest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Prudential Financial Inc. bought a new position in MaxCyte during the 2nd quarter worth approximately $26,000. State of Wyoming bought a new stake in shares of MaxCyte in the 2nd quarter valued at approximately $38,000. Jain Global LLC bought a new stake in shares of MaxCyte in the 4th quarter valued at approximately $45,000. BNP Paribas Financial Markets raised its position in shares of MaxCyte by 39.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock valued at $57,000 after acquiring an additional 10,263 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of MaxCyte during the 4th quarter valued at approximately $67,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

Analysts Set New Price Targets

MXCT has been the subject of a number of research reports. Weiss Ratings downgraded shares of MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, MaxCyte currently has a consensus rating of “Hold” and a consensus price target of $5.00.

MaxCyte Stock Down 3.8%

Shares of NASDAQ MXCT opened at $1.27 on Wednesday. The firm’s 50-day moving average price is $1.20 and its two-hundred day moving average price is $0.98. MaxCyte, Inc. has a 52-week low of $0.64 and a 52-week high of $1.86. The stock has a market capitalization of $136.04 million, a P/E ratio of -3.85 and a beta of 1.48.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Wednesday, August 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company had revenue of $6.50 million during the quarter, compared to analyst estimates of $6.51 million. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%. As a group, equities research analysts expect that MaxCyte, Inc. will post -0.25 earnings per share for the current year.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.